

Amendments to the Specification:

On page 1, after the title, please insert the following paragraph:

CROSS REFERENCE TO RELATED APPLICATIONS

This application is the National Phase of PCT/EP2004/009170, filed August 16, 2004, and published as WO 2005/016366, which in turn claims priority to European Patent Application No. 03018451.9, filed August 14, 2003. The entirety of these applications is incorporated herein by reference.

Please delete the paragraph on page 12, lines 4-16, and replace it with the following paragraph:

The introduction of a nucleic acid encoding an SGT antagonist can be facilitated by the use of so-called translocating peptides. The use of such peptides is particularly preferred for therapeutic purposes. The peptides are usually linked to the nucleic acid to be delivered in a non-covalent manner. In general, peptides are contemplated which mimic and act as efficiently as viruses for gene delivery without their limitations of inducing immune responses or being cytotoxic. Examples of peptides forming peptide-DNA complexes for an efficient delivery into a cell comprise DNA-condensing motifs such as polyamines and modifications thereof, active-targeting motifs such as RGD, endosomolytic peptides such as INF, JTS1 or GALA, and nuclear localization sequences (NLS), e.g. derived from the large tumor antigen of Simian 40 virus. An extensive list of translocating peptides and their proposed delivery mechanisms, all of which are contemplated within the scope of the present invention are described in Morris et al., Curr. Opin. Biotech., Vol. 11(5), pages 461-466. ~~Morris et al., 2000, Curr. Opin. Biotech., Vol. 8, pages 21 to 27.~~